Comparison of Letermovir Versus High-Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation | Synapse
March 3, 2026
Comparison of Letermovir Versus High-Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation
Key Points
Letermovir shows improved efficacy in preventing cytomegalovirus infection post-transplantation.
In this study, lettermovir treatment reduced CMV reactivation rates by 30% compared to high-dose valacyclovir.
Analysis of allogeneic hematopoietic stem cell transplant patients indicates significant differences in medication outcomes.
Understanding these treatment differences highlights the need for tailored prophylactic strategies.